modia™ - Opioid use disorder

Short facts

 

Technology

GAIA´s proprietary artificial intelligence (AI)-expert system, broca®

Indication

Opioid use disorder (OUD)

Period of use

6 months

Commercial rights

Orexo owns the global rights

Partner

Developed together with 

Launch

US launch expected to be initiated in H2 2021

Key advantages

  • Based on cognitive behavioral therapy

  • Highly individualized

  • Complement to traditional pharma treatments

Pivotal study

Large pivotal study initiated in June 2021 where the efficacy of modia™ is evaluated along with bup/nal pharma treatment


Unmet need

The medically assisted treatment of opioid use disorder requires a complete treatment plan, including effective pharmaceutical treatment, such as Orexo’s commercially available ZUBSOLV®, along with counseling or psychosocial support. The access and quality of counseling and psychosocial support remain one of the main barriers to successful treatment in many areas of the US. Orexo believes that the fully-automated digital therapy can become a valuable addition to existing treatment plans, which will improve patients’ access to treatment and overall treatment outcomes.

About the Pivotal modia™ Study

Large pivotal study initiated in June 2021, where the efficacy of modia™ is evaluated along with bup/nal pharma treatment.

Related links

About GAIA

https://gaia-group.com/en/

The press release communicating the partnership

https://orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345

Press release regarding the first patient in modia's pivotal study

https://mb.cision.com/Main/694/3377614/1439218.pdf